Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 6592 record(s)

Req # A-2024-000699

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 24-105059-18, Health Canada’s 2024-27 Corporate Risk Profile.

Organization: Health Canada

83 page(s)
January 2025

Req # A-2024-000706

Adverse Drug Reactions (ADRs) for Leuprorelin. Report numbers: E2B_06985893, E2B_06463299, E2B_06478815, E2B_07089342, E2B_07139781, E2B_07091591, E2B_06698587, E2B_07133130, E2B_07044870, E2B_07041649.

Organization: Health Canada

79 page(s)
January 2025

Req # A-2024-000707

Adverse Drug Reactions (ADRs) for Leuprorelin. Report numbers: E2B_07035040, E2B_06899159, E2B_06926857, E2B_06836971, E2B_07168878, E2B_07119993, E2B_07248238, 001083465, E2B_07058290, E2B_07080809.

Organization: Health Canada

79 page(s)
January 2025

Req # A-2024-000710

Adverse Drug Reactions (ADRs) for Leuprorelin. Report numbers: E2B_06779053, E2B_06907444, E2B_07004123. ADRs for Leuprolide acetate. Report numbers: E2B_07148683, E2B_07154505, E2B_07148672, E2B_06868975, E2B_07148681.

Organization: Health Canada

122 page(s)
January 2025

Req # A-2024-000755

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-109977-88, Canadian Institute for Health Information Release of Report: “Prescribed Drug Spending in Canada, 2023".

Organization: Health Canada

27 page(s)
January 2025

Req # A-2024-000756

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-104766-527, Results of Public Opinion Research on Knowledge and Attitudes of Canadians Towards Drug Decriminalization.

Organization: Health Canada

32 page(s)
January 2025

Req # A-2024-000763

Adverse Drug Reaction (ADR). Report number: E2B_07253848.

Organization: Health Canada

9 page(s)
January 2025

Req # A-2024-000769

Adverse Drug Reactions (ADRs). Report numbers: E2B_05422984, 001041491, E2B_06352172, E2B_06355840, E2B_06370379, E2B_06390563, E2B_06394985.

Organization: Health Canada

1448 page(s)
January 2025

Req # A-2024-000784

From May 29, 2023 to September 23, 2024, provide the HC procedures and protocols for the analysis of substances that may contain metonitazene. I am not requesting versions or drafts before May 29, 2023.

Organization: Health Canada

2681 page(s)
January 2025

Req # A-2024-000787

Adverse Drug Reactions (ADRs) for Mesalazine. Report numbers: E2B_07270577, E2B_07290183, E2B_07292296, 001102535, E2B_07290569, E2B_07315569, E2B_07285367. ADRs for Mesalamine. Report numbers: E2B_07276842, E2B_07305609, E2B_07289987.

Organization: Health Canada

137 page(s)
January 2025
Date modified: